FPFrancimeire Gomes Pinheiro

Francimeire Gomes Pinheiro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francimeire Gomes Pinheiro has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Microemulsion-Based Hydrogels: Physicochemical Properties, Structural Organization and Drug Delivery Applications (2020-2025)

    by Afrânio L. Carvalho, Bruno B. Jensen, Kátia Solange C. R. dos Santos, Mayara A. da Silva, Rebecca Sayuri B. Hanada, Claudia D. Comandolli-Wyrepkowski, Daniel Gabriel A. Carvalho, Francimeire G. Pinheiro, Antonia Maria R. F. Pereira

    Pharmaceutical nanotechnology has enabled drug delivery systems with improved solubility, stability, and release performance. Microemulsion-based hydrogels (MHs) are hybrid colloidal‑polymeric platforms that combine the solubilization capacity and thermodynamic stability of microemulsions with the structural, rheological, and bioadhesive properties of hydrogels. This structured narrative review critically evaluated studies published from 2020 to 2025, emphasizing composition, physicochemical characteristics, structural organization, drug release and permeation, stability, therapeutic applications, and translational aspects. Of 200 publications initially identified, 19 met the predefined eligibility criteria. Reported formulations exhibited pH values of 4.5-6.7 and hydrodynamic diameters of 2.96-357 nm, with approximately 55% below 100 nm. Zeta potentials ranged from near-neutral values to −56 mV, indicating that colloidal stability depends on both electrostatic and steric mechanisms. The oil phase, surfactant / cosurfactant system, and polymeric matrix strongly influenced structural organization, physicochemical stability, rheological behavior, and drug release and permeation. Droplet-polymer interactions further affected network organization and diffusional properties. MHs were investigated mainly for topical and transdermal delivery, with additional applications via intranasal, intramuscular, and intratympanic routes. However, substantial heterogeneity in formulation composition, characterization methods, rheological evaluation, longterm stability studies, and scale-up information limits direct comparison across studies. Advancing MHs toward clinical and industrial translation requires greater methodological standardization, reproducibility, stability assessment, scalable manufacturing, and regulatory alignment. Overall, MHs represent versatile pharmaceutical platforms with promising potential for localized drug delivery at the interface of colloidal chemistry, polymer science, and pharmaceutical technology.

  • Open Access

    Topical microemulsion with phenolic compounds from Libidibia ferrea (Fabaceae): An alternative treatment for cutaneous leishmaniasis

    by Bruno Bezerra Jensen, Katia Solange Cardoso Rodrigues dos Santos, Claudia Dantas Comandolli-Wyrepkowski, Felipe Moura Araujo da Silva, Caio Coutinho de Souza, Maria da Paz Lima, José Fernando Marques Barcellos, Tatiane Pereira de Souza, Fabrício Nonato Araújo Rolim, Francimeire Gomes Pinheiro, et al.

    Background: The pharmacotherapy of cutaneous leishmaniasis is invasive and presents several adverse reactions, which reinforces the need for topical and less toxic alternatives. Methods: Topical microemulsions containing phenolic compounds from Libidibia ferrea (Fabaceae) were developed, physicochemically characterized, and tested in hamsters ( Mesocricetus auratus ) experimentally infected with Leishmania amazonensis . After treatment, clinical progression of lesions, histopathological alterations, and parasite load were evaluated. The dichloromethane (DCM) fraction of the extract was analyzed by mass spectrometry, and the main compounds were isolated. Results: The optimized microemulsion effectively controlled lesion progression, showing only a 25% increase in lesion volume, compared to a 383% increase for the group without treatment, and presented a moderate inflammatory response. A new phenolic compound, named libidine (phenylpropanoic acid derivative), along with methyl gallate, was isolated from the DCM fraction. Conclusions: The topical formulation was as effective as Glucantime® (antimonial standard treatment) and produced a significant reduction in parasite load, consistent with the antileishmanial activity previously reported for phenolic acids and their derivatives.


  • Evaluation of the in vivo and in vitro effect of Libidibia ferrea on Leishmania (Leishmania) amazonensis

    by Thiago De Jesus Bacha, Bruno Bezerra Jensen, Amanda Silva de Jesus, Pamela Emily Torres Iwabuchi, Katia Solange Cardoso Rodrigues dos Santos Geraldi, Francimeire Gomes Pinheiro, Peter Kima, Antonia Maria Ramos Franco

    Currently, the therapeutic arsenal available for the treatment of leishmaniasis is limited. Thus, the aim of this study was to evaluate the in vitro and in vivo antileishmanial efficacy of the methanolic extract and dichloromethane fraction of Libidibia ferrea (DCM). To achieve this goal, the cytotoxicity of these extracts was determined in in vitro assays. Subsequently, its effects on a Leishmania (Leishmania) amazonensis infection of macrophages were evaluated. In vivo studies were performed with golden hamsters infected with L. (L.) amazonensis, which were treated with a microemulsion containing DCM. Furthermore, this fraction was also evaluated in combination with Glucantime®. The extracts reduced macrophage infections and induced reversal of IL-6 suppression in infected cells. There was a significant reduction in the volume of the lesion in the animals treated intralesionally with the combination of DCM+20 mg/SbV/kg/day. Taken together, the results obtained show that L. ferrea extracts (DCM) were not cytotoxic to macrophages and limited macrophage infection. The microemulsion containing the dichloromethane fraction of L. ferrea enhanced the curative effects of Glucantime®


  • Open Access

    Avaliação in vitro da resposta linfoproliferativa de células mononucleares à antígenos solúveis de Leishmania (V.) guyanensis

    by Rafaela Benício Santana, Erika Oliveira da Silva, Paula Figliuolo da Cruz Borges, Francimeire Gomes Pinheiro, Antonia Maria Ramos Franco

    A leishmaniose é uma doença infecto-parasitária causada por protozoários intracelulares do gênero Leishmania sp. Apresenta-se de duas formas clássicas, a leishmaniose cutânea (LC) e leishmaniose mucosa (LM). A diversidade em formas clínicas encontrada na LTA dá-se da interação da espécie de Leishmania envolvida na infecção, resposta imune de cada indivíduo frente ao parasito e até mesmo o vetor. Dos componentes de defesa do hospedeiro importantes para a eliminação da Leishmania sp., podemos destacar a resposta imune adaptativa, que é fluentemente mediada por células. Sabe-se que a resistência ou susceptibilidade da doença está relacionada com o nível de expansão e diferenciação em subpopulações de células efetoras, onde células T CD4+ podem se diferenciar em células T do tipo Th1, ou Th2. Este projeto teve como objetivo avaliar o perfil da linfoproliferação de células mononucleares do sangue periférico (PBMC) de pacientes com LC e de indivíduos saudáveis sensibilizadas por antígenos solúveis de Leishmania (V.) guyanensis, a fim de compreender a modulação celular induzida por essa espécie, agente etiológico da LTA prevalente na região amazônica. A resposta linfoproliferativa foi avaliada em cultura de célulás estímuladas com Antigeno soluvel de L. guyanenesis e Phytohemagglutinin - PHA (10 mg/mL) utilizando BrdU Cell Proliferation ELISA Kit. Os resultados mostraram que todos os indivíduos apresentaram linfoproliferação em resposta ao mitógeno. Em relação ao antígeno, os pacientes antes e após o tratamento apresentaram elevada resposta linfoproliferativa. Dessa forma, podemos sugerir que houve a expansão dos linfócitos T in vitro dos grupos primoinfectados e após tratamento.

  • Evaluation of the lymphoproliferation of mononuclear cells in cutaneous leishmaniasis patients treated with Libidibia ferrea

    by Erika Oliveira Da Silva, Paula Figliuolo da Cruz Borges, Rafaela Benício Santana, Heriederson Sávio Dias Moura, José Fernando Marques Barcellos, Bruno Bezerra Jensen, Francimeire Gomes Pinheiro, Maricleide Farias Naiff, Thaís Tibery Espir, Antonia Maria Ramos Franco

    American integumentary leishmaniasis (ATL) is a neglected disease that mostly affects vulnerable populations. Its broad spectrum of clinical manifestations is related to the type of immune response produced by the host and the species of Leishmania involved. In recent years, the use of medicinal plants has become a therapeutic alternative in the treatment of infectious parasitic diseases. This research aimed to evaluate the lymphoproliferative responses of peripheral blood mononuclear cells (PBMCs) of patients with cutaneous leishmaniasis (CL) before and after treatment, and healthy individuals. The lymphoproliferative response was evaluated in cell culture using stimuli of the dichloromethane fraction (DCM) obtained from Libidibia ferrea, Glucantime® and phytohemagglutinin - PHA using a BrdU Cell Proliferation after 72 h of incubation. In cultures treated with the DCM fraction, intense induction of lymphoproliferation was observed (p<0.0001), as was also observed in response to the PHA mitogen, and there was a significant difference when compared with the conventional treatment (p<0.0135). In the post-treatment and healthy groups, although the compound induced lymphoproliferation, there was no statistical difference. These results suggest that the organic compound played an important inducing role in lymphoproliferation, which highlights the importance of continuity involving new studies in order to evaluate its immunomodulatory activity.


  • Open Access

    A matemática no cotidiano do profissional de sáude

    by Marcus Tulio Alves, Francimeire Gomes Pinheiro